Tuesday, CEL-SCI Corp., a biotechnology company, released a letter to its shareholders informing the share holders that the company has bought another 87,600 shares of CEL-SCI in the open market. This decision was taken in lieu of the present market conditions that has pulled down the company's stock, despite recently presented excellent long-term survival data for cancer drug Multikine. Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/284979/)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Zimmer Biomet’s 3D Printed Titanium Spinal Implant Receives 510(k) Clearance
The system includes surgical tools to insert, move and remove the implants.
Senate Subcommittee Advances $5.4 Billion FDA Spending Bill
The full Senate appropriations committee will consider the bill on Thursday.